<table>
<thead>
<tr>
<th>Indication</th>
<th>Malaria due to Plasmodium ovale</th>
<th>ICD11 code: 1F43</th>
</tr>
</thead>
<tbody>
<tr>
<td>INN</td>
<td>Primaquine</td>
<td></td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
<td></td>
</tr>
<tr>
<td>List type</td>
<td>Core (EML) (EMLc)</td>
<td></td>
</tr>
<tr>
<td>Additional notes</td>
<td>Only for use to achieve radical cure of P. vivax and P. ovale infections, to be administered for 14 days</td>
<td></td>
</tr>
<tr>
<td>Formulations</td>
<td>Oral &gt; Solid: 7.5 mg tablet (as phosphate) ; 15 mg tablet (as phosphate)</td>
<td></td>
</tr>
<tr>
<td>EML status history</td>
<td>First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 2007 (TRS 946) Changed in 2007 (TRS 950)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>All</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>Also recommended for children</td>
<td></td>
</tr>
<tr>
<td>Therapeutic alternatives</td>
<td>The recommendation is for this specific medicine</td>
<td></td>
</tr>
<tr>
<td>Patent information</td>
<td>Patents have expired in most jurisdictions Read more about patents.</td>
<td></td>
</tr>
<tr>
<td>Wikipedia</td>
<td>Primaquine</td>
<td></td>
</tr>
<tr>
<td>DrugBank</td>
<td>Primaquine</td>
<td></td>
</tr>
</tbody>
</table>

Summary of evidence and Expert Committee recommendations

Primaquine was added to the core list of the EMLc for the curative treatment of P. ovale.